androstenediol has been researched along with Acute Radiation Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlem, C; Destiche, D; Frincke, JM; Garsd, A; Groothuis, JR; Kennedy, M; Miller, BS; Onizuka-Handa, N; Reading, C; Schlangen, KM; Stickney, DR | 1 |
| Grace, MB; Jackson, WE; Kao, TC; Rhee, JG; Singh, VK; Whitnall, MH | 1 |
1 trial(s) available for androstenediol and Acute Radiation Syndrome
| Article | Year |
|---|---|
Preliminary clinical findings on NEUMUNE as a potential treatment for acute radiation syndrome.
Topics: Acute Radiation Syndrome; Adult; Aged; Androstenediol; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged | 2010 |
1 other study(ies) available for androstenediol and Acute Radiation Syndrome
| Article | Year |
|---|---|
5-AED enhances survival of irradiated mice in a G-CSF-dependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis.
Topics: Acute Radiation Syndrome; Androstenediol; Animals; Apoptosis Regulatory Proteins; Cell Cycle Proteins; DNA Damage; Granulocyte Colony-Stimulating Factor; Immunity, Innate; Male; Mice; Radiation-Protective Agents; Survival Rate; Up-Regulation | 2012 |